Oussalah et al. found that in 289 patients with cirrhosis, 98 of whom had HCC, ctDNA testing for the SEPT9 promoter site methylation displayed a sensitivity of 94.1% and a specificity of 84.4% in distinguishing HCC from cirrhotic patients [64]. This evidence concerns the gene SEPTIN9 and hepatocellular carcinoma.